1. Home
  2. PRME vs CAPR Comparison

PRME vs CAPR Comparison

Compare PRME & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

SELL

Current Price

$8.36

Market Cap

584.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
CAPR
Founded
2019
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
584.9M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
PRME
CAPR
Price
$4.23
$8.36
Analyst Decision
Buy
Buy
Analyst Count
13
10
Target Price
$7.03
★ $27.25
AVG Volume (30 Days)
★ 5.5M
3.6M
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.18
N/A
EPS
★ N/A
N/A
Revenue
★ $4,632,000.00
N/A
Revenue This Year
$18.58
N/A
Revenue Next Year
$23.34
$85.77
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 55.28
N/A
52 Week Low
$2.67
$2.96
52 Week High
$5.91
$40.37

Technical Indicators

Market Signals
Indicator
PRME
CAPR
Relative Strength Index (RSI) 51.32 50.24
Support Level $2.94 $7.78
Resistance Level $4.80 $10.42
Average True Range (ATR) 0.53 1.01
MACD -0.08 0.23
Stochastic Oscillator 22.25 45.99

Price Performance

Historical Comparison
PRME
CAPR

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: